• Additional funding of €4m from new co-lead investor Biovance Capital, and €1.5m from existing co-lead Kurma Partners, to reach a total of €5.5m. 
   
• Funds will be used to further develop Laigo’s SureTACs™ targeted protein degradation candidates in oncology and auto-immunity.
     

UTRECHT, the Netherlands - 23 March 2026 – Laigo Bio (“Laigo”), a biotech company pioneering novel and highly differentiated therapies using its proprietary SureTACs™ precision membrane protein degradation platform, today announces the successful completion of the second close of its seed financing round, securing an additional €5.5m, bringing the total raised to €17m. This latest investment comes from new co-lead investor Biovance Capital and existing co-lead investor Kurma Partners. 

The proceeds of the seed financing will be used to accelerate the development of Laigo’s Surface Removal Targeting Chimeras (SureTACs) oncology programs towards the clinic, as well as advance its three candidate programs for selected autoimmune and immunology indications, and graft rejection.

Laigo’s proprietary SureTACs platform generates bispecific antibodies that pair the optimal E3 ligase with a disease-causing target protein to stimulate its ubiquitination and lysosomal degradation with a high degree of specificity. Laigo’s platform allows the development of first-in-class, dual targeted therapies that eliminate disease-driving membrane targets. 

Dr. Matthew Baker, Chief Executive Officer of Laigo Bio, said: “The second close of our seed financing round further validates the potential of our SureTACs platform and its ability to identify first-in-class dual targeted therapies to redefine the treatment of cancer and autoimmune diseases. The additional investment and support from new co-lead investor Biovance Capital, alongside further funding from our existing co-lead investor Kurma Partners, will accelerate our oncology programs towards the clinic and enhance our discovery efforts in auto-immunity and immunology. We welcome Dr. João Incio to the Board of Directors.”

Dr. João Incio, General Partner at Biovance Capital, added: “Laigo Bio has shown that its SureTACs degradation technology results in remarkable in vivo and in vitro efficacy, with a high degree of selectivity and improved toxicity and safety. We at Biovance Capital see phenomenal potential in Laigo’s technology and support its commitment to exploring an ever-evolving universe of new targets, including those currently considered undruggable.”

Laigo is backed by a strong syndicate of leading international investors: Kurma Partners, Biovance Capital, Curie Capital, Argobio Studio, Angelini Ventures, Eurazeo, Oncode Bridge Fund, ROM Utrecht Region, and Cancer Research Horizons. Laigo completed the initial close of its seed financing round in December 2025.